NEW

Johnson & Johnson to Acquire Shockwave Medical

Johnson & Johnson and Shockwave Medical, Inc. today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335 per share in cash, corresponding to an enterprise value of...

Medline Expands Catheter Portfolio

Medline and Consure Medical have announced a new agreement for Medline to exclusively distribute the QiVi MEC male external urine management device to help guard against catheter-associated urinary tract infections (CAUTI) and incontinence-associated dermatitis (IAD)....

FDA Clears Single-use Flexible Ureteroscope

Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later...

Brainlab, Fujifilm Offer Advanced Neurosurgery Capabilities

FUJIFILM Healthcare Americas Corporation and Brainlab recently announced that Brainlab will be the exclusive U.S. distributor of ARIETTA Precision Ultrasound for neurosurgery applications to be utilized with Brainlab’s surgical navigation systems. ARIETTA Precision,...

Stryker Launches Voluntary Field Action After Patient Deaths

Stryker announced earlier this month that the company is launching a voluntary field action on specific units of the LIFEPAK 15 Monitor/Defibrillators. At least one published report indicates that the company noticed the issue after receiving complaints from 58 customers and six patients reportedly died due to the delay in therapy.

The company is notifying certain LIFEPAK 15 customers of an issue that may cause the device to lock up after a defibrillation shock is delivered. The lock-up condition is defined as a blank monitor display with LED lights on, indicating power to the device, but no response in the keypad and device functions. A device in this condition has the potential to delay delivery of therapy, and this delay in therapy has the potential to result in serious injury or death.

The company is contacting customers with impacted devices to schedule the correction of their device(s), which will include an update to the firmware for a component on the System Printed Circuit Board Assembly. Stryker anticipates that all devices subject to this field action will be serviced by December 31, 2019. If a customer experiences this issue, they should contact Stryker as soon as possible at 1 800 442 1142 and selecting option 7.

Since the initial commercialization of LIFEPAK 15 in 2009, Stryker has become aware of 58 complaints reported globally for this issue, including 6 events in which the patient died following a delay in therapy. In all six of these cases, at least one shock was delivered prior to the device experiencing the lock-up condition. There are 13,003 devices potentially impacted by this issue and within scope of this field action.

The company is instructing customers to continue to use their LIFEPAK 15 Monitor/Defibrillator according to the Operating Instructions until the correction can be completed. Device Automatic Self-Tests do not identify this fault, as it occurs during defibrillation. Customers should continue to perform the daily check as described in the Operator’s Checklist, specifically, the QUIK-COMBO therapy cable check as described in the General Maintenance and Testing Section (pages 10-4 and the LIFEPAK 15 Monitor/Defibrillator Operator’s Checklist, number 7).

If a device exhibits the lockup condition during patient use, the steps from the General Troubleshooting Section (page 10-18) of the LIFEPAK 15 Monitor/Defibrillator Operating Instructions should be immediately followed:

Press and hold ON until the LED turns off (~5 seconds). Then press ON to turn the device back on.

If the device does not turn off, remove both batteries and disconnect the device from the power adapter, if applicable. Then reinsert batteries and/or, reconnect the power adapter, and press ON to turn the device back on.

Information about this notice is available at: http://www.strykeremergencycare.com/productnotices. Impacted customers will be notified by letter and will be requested to verify their device status. Customers with questions regarding this notification, please contact Stryker by calling 1 800 442 1142, option 7, 6:00 a.m. to 4:00 p.m. (Pacific) Monday – Friday, or by email to rsfa281@stryker.com or fax to 1 425 867 4948.

In addition to contacting Stryker, any potential quality problems or adverse reactions or events associated with the use of a product from Stryker may be reported to the U. S. Food and Drug Administration’s MedWatch Safety Information and Adverse Event Reporting Program online at https://www.fda.gov/safety/medwatch/, by phone 1 800 332 1088 or fax 1 800 FDA 0178.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X